

Remarks

Claims 1, 5-8, 12-15, 19-22, 26-29 and 33-35 are pending.

Claims 1, 8, 15, 22 and 29 have been amended and are supported by the specification at, for example, page 6, line 29 to page 7, line 23.

No issues of new matter should arise and entry of the amendment is respectfully requested.

A. First Rejection under 35 U.S.C. §112, First Paragraph

Claims 1, 5-8, 12-15, 19-22, 26-29 and 33-35 are rejected under 35 USC § 112, first paragraph, as failing to comply with the written description requirement.

Applicants respectfully traverse the rejection and respectfully submit that the claims comply with the written description requirement.

As pointed out by the Examiner, the specification at pages 17-21 discloses S-nitroso-ACE inhibitors and the specification at page 23 discloses NO adducts having at least one -O-NO₂ group, wherein the NO adducts includes compounds, such as, for example, polypeptides. One skilled in the art knows that ACE inhibitors are polypeptides. Given the extensive disclosure for S-nitroso-ACE in the specification, on reading the specification it would be obvious for one skilled in the art to conclude that the NO adducts of the invention encompass ACE inhibitors (i.e. polypeptides) having at least one -O-NO₂ group.

In view thereof, Applicants respectfully submit that the claims satisfy the requirement under 35 U.S.C. § 112, first paragraph, and respectfully request that the rejection under this provision be withdrawn.

A. Second Rejection under 35 U.S.C. §112, First Paragraph

Claims 1, 5-8, 12-15, 19-22, 26-29 and 33-35 are rejected under 35 USC § 112, first paragraph, as lacking enablement.

Applicants respectfully traverse the rejection and respectfully submit that the claims are fully enabled.

As pointed out by the Examiner on page 3, of the Office Action, the specification is enabled for the local delivery of nitric oxide adduct. In view of the amendment of the claims to recite "locally administering" the rejection is now moot.

In view thereof, Applicants respectfully submit that the claims satisfy the requirement under 35 U.S.C. § 112, first paragraph, and respectfully request that the rejection under this provision be withdrawn.

B. Conclusion

Applicants respectfully request reconsideration and allowance of claims 1, 5-8, 12-15, 19-22, 26-29 and 33-35. The Examiner is encouraged to contact the undersigned concerning any questions about the present application.

Respectfully submitted,



Belinda M. Lew, Ph.D.
Registration No. 53,212

Dated: April 21, 2006
Wilmer Cutler Pickering Hale and Dorr LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8449